Investors & Media

Press Releases


 
Press Releases
  Date Title View
Mar 2, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced that, on March 1, 2017, the Compensation Committee of Sage's Board of Directors granted non-...
Feb 23, 2017
Continued momentum expected in 2017 with several programs anticipating clinical trial results this year, including two Phase 3 programs Phase 2 placebo-controlled study of SAGE-217 in major depressive disorder expected to begin in 1H 2017 First NMDA candidate, SAGE-718, pl...
Feb 17, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on Thursday, February 23, 2017 ...
Feb 16, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE) - On February 16, 2017, Chief Executive Officer Jeff Jonas conducted an interview about SAGE-217 in major depressive disorder (MDD). During the course of the interview, Dr. Jonas acknowledged the industry's interest in the MDD data. Dr. Jonas' ...
Feb 13, 2017
Open-label Pilot Study of Once Daily, Orally Administered Molecule Demonstrates Positive Signal of Activity and Tolerability CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat lif...
Feb 7, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that it will participate in the following upcoming conferences: ...
Jan 3, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company is scheduled to present at the J.P. Morgan 2017 Healthcare Conference in ...
Dec 29, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Jeff Jonas, M.D., Chief Executive Officer of Sage, will participate in a fireside chat at ...
Dec 19, 2016
First patient dosed in Phase 2 proof-of-concept trial of SAGE-217 in major depressive disorder and trial sites open for Phase 2 trial of SAGE-217 in postpartum depression Four Phase 2 clinical programs now underway for SAGE-217 in mood and movement disorders CAMBRIDG...
Dec 13, 2016
First patient dosed in Phase 2 proof-of-concept trial of SAGE-217 in Parkinson's disease Trial sites are open and screening patients for the Phase 2a trial in essential tremor; patients expected to be dosed imminently CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ...
1
... NextLast
= add release to Briefcase